Following up on their discussion of COVID-19 vaccines and therapeutics, Venrock partner Bryan Roberts speaks with Mathai Mammen, Global Head of R&D at the Janssen Pharmaceutical Companies of Johnson & Johnson, about Mammen's career path and what differences he's found working on drug development in both small companies and large companies. Managing 14,000 people has its challenges, but the scale is incredible: J&J's products touch more than 1 billion people worldwide. They also discuss trends in gene editing and CRISPR thanks to machine learning and AI.